Telix Pharmaceuticals (TLX) Total Debt (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Total Debt for 3 consecutive years, with $405.0 million the latest figure, recorded in Q4 2025.

• Quarterly Total Debt changed 0.47% year-over-year to $405.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $405.0 million (changed 0.47% YoY) and the FY2025 annual result came in at $405.0 million, changed 0.47% from the prior year.
• Total Debt was little changed at $405.0 million in Q4 2025 per TLX's latest filing, from $403.1 million in the prior quarter.
• Over the last five years, Total Debt for TLX reached as high as $405.0 million in Q4 2025 and fell as low as $6.5 million in Q4 2023.
• A 3-year average of $271.5 million and a median of $403.1 million in 2024 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2024 — Total Debt soared 6122.73% — and 2025, when it gained 0.47%.
• Year by year, Total Debt stood at $6.5 million in 2023, then jumped by 6122.73% to $403.1 million in 2024, then increased by 0.47% to $405.0 million in 2025.
• According to Business Quant data, Total Debt over the past three periods registered $405.0 million, $403.1 million, and $6.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.